CCP
ELDN icon

Clarity Capital Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Clarity Capital Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$31.2K Hold
11,500
– – 0.01% 111
2025
Q1 		$39K Hold
11,500
– – 0.02% 117
2024
Q4 		$47.4K Hold
11,500
– – 0.02% 121
2024
Q3 		$28.6K Buy
+11,500
New +$30.8K 0.02% 124

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Clarity Capital Partners's ELDN Position: Q2 2025 in Review

Clarity Capital Partners held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2025 at 11,500 shares worth $31.2K. The position accounts for 0.01% of the portfolio, ranked #111.

Clarity Capital Partners first reported a position in ELDN in Q3 2024 and has held it in 4 quarters since. The position peaked at $47.4K in Q4 2024. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • Clarity Capital Partners held 11,500 shares of Eledon Pharmaceuticals worth $31.2K as of Q2 2025.
  • Clarity Capital Partners left its Eledon Pharmaceuticals share count unchanged in Q2 2025.
  • Eledon Pharmaceuticals made up 0.01% of Clarity Capital Partners's portfolio in Q2 2025, its #111 holding.
  • Clarity Capital Partners first reported a position in Eledon Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Clarity Capital Partners's Eledon Pharmaceuticals position peaked at $47.4K in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on Clarity Capital Partners's 13F filing for Q2 2025, filed 21 Jul 2025.